These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 31712208)

  • 1. Second-Generation Antidiabetic Sulfonylureas Inhibit Candida albicans and Candidalysin-Mediated Activation of the NLRP3 Inflammasome.
    Lowes DJ; Hevener KE; Peters BM
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candidalysin Crucially Contributes to Nlrp3 Inflammasome Activation by Candida albicans Hyphae.
    Rogiers O; Frising UC; Kucharíková S; Jabra-Rizk MA; van Loo G; Van Dijck P; Wullaert A
    mBio; 2019 Jan; 10(1):. PubMed ID: 30622184
    [No Abstract]   [Full Text] [Related]  

  • 3. Mechanism of Vaginal Epithelial Cell Pyroptosis Induced by the NLRP3 Inflammasome in Vulvovaginal Candidiasis.
    Peng Y; Xu Y; Li S; Shao M; Shen Z; Qi W
    Am J Reprod Immunol; 2024 Jul; 92(1):e13893. PubMed ID: 38958245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptomic analysis of vulvovaginal candidiasis identifies a role for the NLRP3 inflammasome.
    Bruno VM; Shetty AC; Yano J; Fidel PL; Noverr MC; Peters BM
    mBio; 2015 Apr; 6(2):. PubMed ID: 25900651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NLRP3 Inflammasome Inhibition by MCC950 Reduces Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice-Brief Report.
    van der Heijden T; Kritikou E; Venema W; van Duijn J; van Santbrink PJ; Slütter B; Foks AC; Bot I; Kuiper J
    Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1457-1461. PubMed ID: 28596375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The NLRP3 inflammasome modulates glycolysis by increasing PFKFB3 in an IL-1β-dependent manner in macrophages.
    Finucane OM; Sugrue J; Rubio-Araiz A; Guillot-Sestier MV; Lynch MA
    Sci Rep; 2019 Mar; 9(1):4034. PubMed ID: 30858427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of NLRP3 inflammasome by MCC950 improves the metabolic outcome of islet transplantation by suppressing IL-1β and islet cellular death.
    Matsuoka T; Yoshimatsu G; Sakata N; Kawakami R; Tanaka T; Yamada T; Yoshida Y; Hasegawa S; Kodama S
    Sci Rep; 2020 Oct; 10(1):17920. PubMed ID: 33087823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Pharmacology of the NLRP3 Inflammasome Inhibitor CP-456,773 (CRID3) in Murine Models of Dermal and Pulmonary Inflammation.
    Primiano MJ; Lefker BA; Bowman MR; Bree AG; Hubeau C; Bonin PD; Mangan M; Dower K; Monks BG; Cushing L; Wang S; Guzova J; Jiao A; Lin LL; Latz E; Hepworth D; Hall JP
    J Immunol; 2016 Sep; 197(6):2421-33. PubMed ID: 27521339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of NLRP3 inflammasome inhibition by MCC950 on LPS-induced pancreatic adenocarcinoma inflammation.
    Yaw ACK; Chan EWL; Yap JKY; Mai CW
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2219-2229. PubMed ID: 32507974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Analysis of the Capacity of the
    Willems HME; Lowes DJ; Barker KS; Palmer GE; Peters BM
    Infect Immun; 2018 Dec; 86(12):. PubMed ID: 30249743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of the NLRP3 Inflammasome Is Associated with Valosin-Containing Protein Myopathy.
    Nalbandian A; Khan AA; Srivastava R; Llewellyn KJ; Tan B; Shukr N; Fazli Y; Kimonis VE; BenMohamed L
    Inflammation; 2017 Feb; 40(1):21-41. PubMed ID: 27730320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The selective NLRP3 inflammasome inhibitor MCC950 alleviates cholestatic liver injury and fibrosis in mice.
    Qu J; Yuan Z; Wang G; Wang X; Li K
    Int Immunopharmacol; 2019 May; 70():147-155. PubMed ID: 30802677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of n-butanol extract of Pulsatilla decoction on the NLRP3 inflammasome in macrophages infected with Candida albicans.
    Hu K; Zhang H; Shi G; Wang B; Wu D; Shao J; Wang T; Wang C
    J Ethnopharmacol; 2023 Mar; 304():116041. PubMed ID: 36539072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the NLRP3 Inflammasome With Inhibitor MCC950 Prevents Aortic Aneurysms and Dissections in Mice.
    Ren P; Wu D; Appel R; Zhang L; Zhang C; Luo W; Robertson AAB; Cooper MA; Coselli JS; Milewicz DM; Shen YH; LeMaire SA
    J Am Heart Assoc; 2020 Apr; 9(7):e014044. PubMed ID: 32223388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective NLRP3 inflammasome inhibitor reduces neuroinflammation and improves long-term neurological outcomes in a murine model of traumatic brain injury.
    Xu X; Yin D; Ren H; Gao W; Li F; Sun D; Wu Y; Zhou S; Lyu L; Yang M; Xiong J; Han L; Jiang R; Zhang J
    Neurobiol Dis; 2018 Sep; 117():15-27. PubMed ID: 29859317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition.
    Vande Walle L; Stowe IB; Šácha P; Lee BL; Demon D; Fossoul A; Van Hauwermeiren F; Saavedra PHV; Šimon P; Šubrt V; Kostka L; Stivala CE; Pham VC; Staben ST; Yamazoe S; Konvalinka J; Kayagaki N; Lamkanfi M
    PLoS Biol; 2019 Sep; 17(9):e3000354. PubMed ID: 31525186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MCC950 blocks enhanced interleukin-1β production in patients with NLRP3 low penetrance variants.
    Schuh E; Groß CJ; Wagner D; Schlüter M; Groß O; Kümpfel T
    Clin Immunol; 2019 Jun; 203():45-52. PubMed ID: 30974290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction.
    Gao R; Shi H; Chang S; Gao Y; Li X; Lv C; Yang H; Xiang H; Yang J; Xu L; Tang Y
    Int Immunopharmacol; 2019 Sep; 74():105575. PubMed ID: 31299609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microglial NLRP3 inflammasome activation mediates IL-1β release and contributes to central sensitization in a recurrent nitroglycerin-induced migraine model.
    He W; Long T; Pan Q; Zhang S; Zhang Y; Zhang D; Qin G; Chen L; Zhou J
    J Neuroinflammation; 2019 Apr; 16(1):78. PubMed ID: 30971286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
    Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
    J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.